Header Logo

Connection

Fatima Laher to Humans

Back to Details
This is a "connection" page, showing publications Fatima Laher has written about Humans.
Fatima Laher
Connection Strength
1,197
Humans
  1. Early Online. S Afr Med J. 2024 Jul 19; 114(7):e2109.
    View in: PubMed
    Score: 0,070
  2. Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. Vaccine. 2024 Aug 13; 42(20):125991.
    View in: PubMed
    Score: 0,070
  3. Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline. BMC Med Res Methodol. 2023 06 24; 23(1):147.
    View in: PubMed
    Score: 0,065
  4. Use of Varied Screening Risk Criteria and HIV Incidence in Phase 1 and 2 HIV Vaccine Trials in South Africa. AIDS Behav. 2023 Apr; 27(4):1314-1320.
    View in: PubMed
    Score: 0,062
  5. HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021. AIDS Res Hum Retroviruses. 2022 05; 38(5):350-358.
    View in: PubMed
    Score: 0,059
  6. Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial. PLoS One. 2021; 16(1):e0241708.
    View in: PubMed
    Score: 0,055
  7. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important. BMC Public Health. 2020 Nov 07; 20(1):1669.
    View in: PubMed
    Score: 0,054
  8. Review of preventative HIV vaccine clinical trials in South Africa. Arch Virol. 2020 Nov; 165(11):2439-2452.
    View in: PubMed
    Score: 0,054
  9. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
    View in: PubMed
    Score: 0,052
  10. HIV research in South Africa: Advancing life. S Afr Med J. 2019 Dec 05; 109(11b):36-40.
    View in: PubMed
    Score: 0,051
  11. Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. PLoS One. 2014; 9(11):e112303.
    View in: PubMed
    Score: 0,036
  12. Conversations with mothers: exploring reasons for prevention of mother-to-child transmission (PMTCT) failures in the era of programmatic scale-up in Soweto, South Africa. AIDS Behav. 2012 Jan; 16(1):91-8.
    View in: PubMed
    Score: 0,029
  13. Role of menstruation in contraceptive choice among HIV-infected women in Soweto, South Africa. Contraception. 2010 Jun; 81(6):547-51.
    View in: PubMed
    Score: 0,026
  14. A qualitative assessment of decisions affecting contraceptive utilization and fertility intentions among HIV-positive women in Soweto, South Africa. AIDS Behav. 2009 Jun; 13 Suppl 1:47-54.
    View in: PubMed
    Score: 0,024
  15. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. 2024 Aug 27; 16(9).
    View in: PubMed
    Score: 0,018
  16. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
    View in: PubMed
    Score: 0,018
  17. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
    View in: PubMed
    Score: 0,017
  18. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jul; 93:104590.
    View in: PubMed
    Score: 0,016
  19. Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa. AIDS Behav. 2023 Sep; 27(9):3027-3037.
    View in: PubMed
    Score: 0,016
  20. A qualitative study of stakeholder and researcher perspectives of community engagement practices for HIV vaccine clinical trials in South Africa. J Community Psychol. 2023 04; 51(3):998-1015.
    View in: PubMed
    Score: 0,016
  21. Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. J Infect Dis. 2022 08 24; 226(2):246-257.
    View in: PubMed
    Score: 0,015
  22. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. S Afr Med J. 2022 02 02; 112(1):13518.
    View in: PubMed
    Score: 0,015
  23. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021 03 25; 384(12):1089-1100.
    View in: PubMed
    Score: 0,014
  24. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014.
    View in: PubMed
    Score: 0,014
  25. Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathog. 2021 03; 17(3):e1009363.
    View in: PubMed
    Score: 0,014
  26. Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Sci Rep. 2020 08 03; 10(1):13031.
    View in: PubMed
    Score: 0,013
  27. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
    View in: PubMed
    Score: 0,013
  28. A mixed methods investigation of implementation barriers and facilitators to a daily mobile phone sexual risk assessment for young women in Soweto, South Africa. PLoS One. 2020; 15(4):e0231086.
    View in: PubMed
    Score: 0,013
  29. HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. Sci Rep. 2020 02 07; 10(1):2093.
    View in: PubMed
    Score: 0,013
  30. Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. Front Immunol. 2019; 10:2741.
    View in: PubMed
    Score: 0,013
  31. An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis. BMC Infect Dis. 2019 Sep 18; 19(1):824.
    View in: PubMed
    Score: 0,013
  32. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
    View in: PubMed
    Score: 0,013
  33. Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915). J Acquir Immune Defic Syndr. 2019 06 01; 81(2):e39-e48.
    View in: PubMed
    Score: 0,012
  34. A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: implications for HIV prevention efforts. BMC Infect Dis. 2018 Oct 03; 18(1):499.
    View in: PubMed
    Score: 0,012
  35. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
    View in: PubMed
    Score: 0,012
  36. Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa. AIDS Behav. 2018 Jul; 22(7):2312-2321.
    View in: PubMed
    Score: 0,012
  37. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
    View in: PubMed
    Score: 0,012
  38. Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa. Trans R Soc Trop Med Hyg. 2017 03 01; 111(3):132-136.
    View in: PubMed
    Score: 0,011
  39. A Cross Sectional Study of the Prevalence of Preputial and Penile Scrotal Abnormalities among Clients Undergoing Voluntary Medical Male Circumcision in Soweto, South Africa. PLoS One. 2016; 11(6):e0156265.
    View in: PubMed
    Score: 0,010
  40. Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016 04; 17:104-109.
    View in: PubMed
    Score: 0,010
  41. Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS Biol. 2016 Mar; 14(3):e1002372.
    View in: PubMed
    Score: 0,010
  42. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 01; 164(5):313-22.
    View in: PubMed
    Score: 0,010
  43. Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS One. 2015; 10(9):e0137666.
    View in: PubMed
    Score: 0,010
  44. Exposure to and experiences of violence among adolescents in lower socio-economic groups in Johannesburg, South Africa. BMC Public Health. 2015 May 01; 15:450.
    View in: PubMed
    Score: 0,009
  45. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine. 2015 Jun 09; 33(25):2944-54.
    View in: PubMed
    Score: 0,009
  46. Health-seeking behaviours by gender among adolescents in Soweto, South Africa. Glob Health Action. 2015; 8:25670.
    View in: PubMed
    Score: 0,009
  47. Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One. 2014; 9(8):e103446.
    View in: PubMed
    Score: 0,009
  48. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014 May; 14(5):388-96.
    View in: PubMed
    Score: 0,009
  49. The effect of a maturing antiretroviral program on early mortality for patients with advanced immune-suppression in Soweto, South Africa. PLoS One. 2013; 8(11):e81538.
    View in: PubMed
    Score: 0,008
  50. Does routine prophylactic oral flucloxacillin reduce the incidence of post-circumcision infections? Am J Infect Control. 2013 Oct; 41(10):897-900.
    View in: PubMed
    Score: 0,008
  51. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011 Mar 09; 6(3):e17518.
    View in: PubMed
    Score: 0,007
  52. Influence of culture on contraceptive utilization among HIV-positive women in Brazil, Kenya, and South Africa. AIDS Behav. 2011 Feb; 15(2):454-68.
    View in: PubMed
    Score: 0,007
  53. Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment services. PLoS One. 2010 Nov 05; 5(11):e13868.
    View in: PubMed
    Score: 0,007
  54. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
    View in: PubMed
    Score: 0,007
  55. Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting. Am J Public Health. 2011 Feb; 101(2):350-8.
    View in: PubMed
    Score: 0,007
  56. Responding to her question: a review of the influence of pregnancy on HIV disease progression in the context of expanded access to HAART in sub-Saharan Africa. AIDS Behav. 2009 Jun; 13 Suppl 1:66-71.
    View in: PubMed
    Score: 0,006
  57. Human papillomavirus genotype distribution among human immunodeficiency virus (HIV)-infected and non-HIV-infected women in Soweto, South Africa. J Clin Microbiol. 2008 Dec; 46(12):4109-10.
    View in: PubMed
    Score: 0,006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.